Ono will have a non-exclusive sublicense to intellectual property relating to the technology. Receptos will also conduct a program to transfer technology to Ono, including determining a protein crystal structure solution for an additional Ono GPCR drug discovery target.
Receptos will receive an upfront fee and milestones for successful technology transfer, and remains eligible to receive R&D milestones designated under the existing collaboration agreement.
"The expansion of the Ono-Receptos collaboration highlights the continued delivery of valuable scientific expertise to our partners," said Faheem Hasnain, president and chief executive officer of Receptos. "Transferring our proprietary GPCR technology provides non-dilutive capital to Receptos, and demonstrates our dedication to innovation in GPCR therapeutics by enabling our strategic partners in the proprietary technology to facilitate rational drug design for this important target